Shopping Cart 0
Cart Subtotal
USD 0

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Pipeline Review, H2 2018

Summary

According to the recently published report '5-Hydroxytryptamine Receptor 6-Pipeline Review, H2 2018'; 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-The 5-HT6 receptor is a subtype of 5-HT receptor that binds the endogenous neurotransmitter serotonin. Blockade of 5-HT6 receptors showed to increase glutamatergic and cholinergic neurotransmission in brain, whereas activation enhances GABAergic signaling in a widespread manner. Antagonism of 5-HT6 receptors facilitates dopamine and norepinephrine release in the frontal cortex while stimulation has the opposite effect. 5-HT6 receptor plays an important role in Alzheimer's disease and other forms of dementia and obesity.

The report '5-Hydroxytryptamine Receptor 6-Pipeline Review, H2 2018' outlays comprehensive information on the 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Cardiovascular, Metabolic Disorders, Respiratory and Undisclosed which include indications Psychiatric Disorders, Schizophrenia, Alzheimer's Disease, Anxiety Disorders, Cognitive Disorders, Dementia, Attention Deficit Hyperactivity Disorder (ADHD), Autism, Bipolar Disorder (Manic Depression), Dementia Associated With Alzheimer's Disease, Depression, Idiopathic Pulmonary Fibrosis, Major Depressive Disorder, Neurology, Obesity, Psychosis, Pulmonary Arterial Hypertension, Schizoaffective Disorder and Unspecified.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)

- The report reviews 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics and enlists all their major and minor projects

- The report assesses 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Overview

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Companies Involved in Therapeutics Development

Acorda Therapeutics Inc

Adamed Sp z oo

Avineuro Pharmaceuticals Inc

Celon Pharma SA

H. Lundbeck AS

Reviva Pharmaceuticals Inc

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Drug Profiles

ADN-1184-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADN-2013-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADN-3662-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-3208-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-211-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-3205-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-322-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-492-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HEC-30654AcOH-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

landipirdine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LuAF-35700-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-5063-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize 5-HT 6 and 5-HT2A for Behavioral and Psychological Symptoms of Dementia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize 5-HT6 for Alzheimer's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize 5-HT6 Receptor for Central Nervous System Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-502-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Dormant Products

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Discontinued Products

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Product Development Milestones

Featured News & Press Releases

Apr 10, 2018: Reviva Pharmaceuticals Receives FDA Orphan Designation for RP5063 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Jan 10, 2018: Avineuro Pharmaceuticals Reported Phase Ib Trial Results of AVN-101

Nov 13, 2017: Suven Life sciences announces presentation on its cognitive disorders drug candidate SUVN-502 at Neuroscience 2017 at Washington DC

Oct 17, 2017: Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of Pulmonary Arterial Hypertension

Nov 17, 2016: Reviva Pharmaceuticals Receives FDA Orphan Designation for Pulmonary Arterial Hypertension (PAH)

May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016

Mar 11, 2016: Lundbeck starts clinical phase III program with Lu AF35700 in patients with treatment resistant schizophrenia

Dec 07, 2015: Suven Initiates Phase 2A trial of SUVN-502 in USA in Alzheimer's Disease

Oct 22, 2015: Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits

Jul 01, 2015: Avineuro Completed Phase II Clinical Study Of AVN-211, A Selective 5-HT6 Receptor Antagonist

Dec 23, 2014: Biotie Announces Start Of Syn120 Phase 2A Trial In Parkinson's Disease Dementia And Provides Outlook Update For Near Term Pipeline Events

Dec 14, 2014: AllaChem Completes Phase Ib/IIa Clinical Study with AV4025, an HCV NS5A Inhibitor

Sep 08, 2014: Suven Life Sciences Provides Update On Its Molecule For Alzheimer's Disease

Jul 30, 2014: Biotie updates outlook on SYN120

Jul 16, 2014: Biotie Therapies Selects Bracket's CDR System for Phase 2 Trial of Treatment of Parkinson's disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Acorda Therapeutics Inc, H2 2018

Pipeline by Adamed Sp z oo, H2 2018

Pipeline by Avineuro Pharmaceuticals Inc, H2 2018

Pipeline by Celon Pharma SA, H2 2018

Pipeline by H. Lundbeck AS, H2 2018

Pipeline by Reviva Pharmaceuticals Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Dormant Products, H2 2018 (Contd..3), H2 2018

Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Therapeutic Products under Development, Key Players in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Therapeutics, 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Pipeline Overview, 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Pipeline, 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Pipeline Assessment


Companies

Acorda Therapeutics Inc

Adamed Sp z oo

Avineuro Pharmaceuticals Inc

Celon Pharma SA

H. Lundbeck AS

Reviva Pharmaceuticals Inc